Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
488
Employees488
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
488
Employees488

AGIO Key Statistics

Market cap
1.59B
Market cap1.59B
Price-Earnings ratio
-3.92
Price-Earnings ratio-3.92
Dividend yield
Dividend yield
Average volume
1.29M
Average volume1.29M
High today
$27.67
High today$27.67
Low today
$26.80
Low today$26.80
Open price
$27.52
Open price$27.52
Volume
1.16M
Volume1.16M
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

With a market cap of 1.59B, Agios(AGIO) trades at $27.27. The stock has a price-to-earnings ratio of -3.92.

On 2025-12-14, Agios(AGIO) stock traded between a low of $26.80 and a high of $27.67. Shares are currently priced at $27.27, which is +1.8% above the low and -1.4% below the high.

The Agios(AGIO)'s current trading volume is 1.16M, compared to an average daily volume of 1.29M.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

During the past year, Agios(AGIO) stock moved between $22.24 at its lowest and $46.00 at its peak.

AGIO News

Simply Wall St 2d
How Investors Are Reacting To Agios Pharmaceuticals FDA Delay On Mitapivat Thalassemia Decision

In early December 2025, Agios Pharmaceuticals reported that the FDA missed its December 7 PDUFA goal date and has yet to issue a decision on the supplemental Ne...

How Investors Are Reacting To Agios Pharmaceuticals FDA Delay On Mitapivat Thalassemia Decision
Simply Wall St 4d
Agios Pharmaceuticals: Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion

Agios Pharmaceuticals (AGIO) is back in focus after the FDA missed its December 7 decision date on the mitapivat thalassemia sNDA, leaving the filing under acti...

Agios Pharmaceuticals: Reassessing Valuation After FDA Delays Thalassemia Decision for PYRUKYND Expansion
TipRanks 6d
Anticipated FDA Approval of Agios Pharma’s Pyrukynd Expected to Boost Stock Value

Agios Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on...

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

TipRanks 6d
Agios Pharmaceuticals says FDA has not yet issued decision for mitapivat sNDA

Agios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration has not yet issued a regulatory decision on the supplemental New Drug Applicat...

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.